3.1. 12Months DAPT
In the last ten years there has been a great number of studies exploring optimal duration of DAPT followed by a single antiplatelet agent. Initially the recommended duration for DAPT after coronary stenting was 1-6 months [
38]. This treatment window was non-randomly tested in the studies that compared drug-eluting stents (DES) with bare metal stents (BMS). The mean follow-up time for clopidogrel based DAPT in the PCI CURE trial was 8 months [
16]. The evidence of an increased risk of late and very late ST after first-generation DES lead to a more cautious approach with extension of DAPT well beyond 12 months after implantation [
39,
40,
41,
42]. Based on the available evidence, consensus-based guidelines recommended a minimum of 12 months of DAPT in this setting [
43]. However, the introduction of safer stent platforms [
44,
45] progressively showed that DAPT duration could be safely shortened [
46]. The main reason to strike an optimal duration of DAPT is to reasonably balance the risk of ischemic and bleeding events, both impacting prognosis, and both opposingly affected by the duration of antithrombotic therapy. In this context, clinical trials comparing 3 or 6 months of DAPT to 12 months found no difference in ischemic events, with improved safety after short-term DAPT [
47].
3.2. Prolonged (>12 months) DAPT
DESs reduced the rate of restenosis as compared with bare-metal stents, however there was an initial concern that first-generation DESs may be associated with an additional risk of late and very-late ST [
48]. In addition, beyond stent-related events, ischemic events unrelated to the treated plaque may also occur, which support the potential for prolonged antiplatelet therapy as a secondary prevention strategy [
49,
50].
Among the others, patients with MI have heightened platelet activation and aggregation compared with patients with CCS, leading to a higher predisposition to atherothrombosis [
51,
52,
53], and it may persist for years afterwards [
54,
55,
56]. Hence, these patients may benefit more intensive antiplatelet therapies following PCI.
The DAPT study was a multicenter randomized trial that enrolled patients treated with DAPT after PCI with DES. At 12 months, patients who had no MACE or cerebrovascular event, repeat revascularization, or moderate or severe bleeding and had been adherent to thienopyridine therapy were randomized to continue thienopyridine or to placebo for another 18 months, to compare 12 months strategy vs 30 months strategy. The coprimary efficacy end points (the cumulative incidence of definite or probable ST and the composite of death, MI, or stroke) were significantly lower in the group that continued thienopyridine (0.4% vs 1.4% for stent thrombosis; 4.3% vs 5.9% for MACCE) and was consistent across stent type and thienopyridine drug used. However, prolonged DAPT lead to a significantly higher rate of bleeding, and all-cause mortality was increased by 36% in the prolonged DAPT group [
57]. Importantly, most of the benefit observed with a prolonged DAPT treatment was observed among patients presenting with a MI [
58,
59].
Ticagrelor, when added to aspirin after an ACS, reduces the rate of major adverse CV events as compared with clopidogrel. However, patients who had a MI, who are at higher risk for recurrent ischemic events, could benefit from a prolonged DAPT with Ticagrelor.
The Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial, a randomized, double-blind, placebo-controlled clinical trial, tested long-term DAPT with ticagrelor, evaluating 2 different doses: 90 mg twice daily and 60 mg twice daily. The patients were considered eligible if had a spontaneous MI 1 to 3 years before, were at least 50 years of age, and had one of the following additional high-risk features: age of 65 years or older, diabetes mellitus (DM) requiring medication, a second prior spontaneous MI, multivessel coronary artery disease, or chronic renal dysfunction. They were randomized in a 1:1:1 ratio to receive ticagrelor orally at a dose of 90 mg twice daily, ticagrelor orally at a dose of 60 mg twice daily, or placebo. The median time from the MI (53.6% of them were STEMI) to randomization was 1.7 years. The two ticagrelor doses, reduced, as compared with placebo, the rate of CV death, MI, or stroke, but increased the rate of bleeding (even TIMI major bleeding, bleeding leading to transfusion, and bleeding leading to discontinuation of the study drug). Ultimately, the overall risk to benefit trade-off was improved with the ticagrelor 60mg bid dose, which lead to the final approval of this drug-dose with the new indication for extended DAPT [
60].
Udell et al. conducted a meta-analysis of 6 RCTs on secondary prevention including 33 435 patients with prior-MI randomized to extended DAPT beyond 1 year or standard DAPT for 12 months. Extended DAPT beyond 1 year resulted in a 22% relative and 1.1% absolute risk reduction for major adverse CV events over a mean 31 months of follow-up with a 0.8% absolute increase in the risk of major bleeding, but without significant excess of ICH or fatal bleeding and no significant differences on non-CV causes of death. Importantly, extended DAPT was associated to a significant reduction of CV mortality [
61].
Taken this into consideration, extended DAPT appears an attractive approach in patients with prior MI and low risk for bleeding. Whether the type of P2Y12i may be associated with a different impact on the overall long-term outcomes is not well established [
62].
3.3. Short (1 or 3 or 6-months) DAPT
A short DAPT strategy of less than 12 months after coronary stent implantation has been compared to the standard of care (i.e., 12 months DAPT) in several RCTs, generally testing non-inferiority for ischemic events and superiority for bleeding.
The EXCELLENT trial (A Comparison of Xience/Promus Versus Cypher in Reducing Late Loss After Stenting) aimed to assess the effectiveness of a short-term DAPT strategy (6 months). A total of 1443 patients were randomly assigned in a 2 × 2 factorial design according to the type of stent (EES vs SES) and the duration of DAPT (6 vs 12 months). One of the points of the study was to determine if the short-term DAPT strategy was not inferior to the standard care concerning the occurrence of cardiac death, MI, or ischemia-driven target vessel revascularization (TVR). The primary end point is in-stent late loss at 9 months for comparison of type of stent, and the coprimary end point is target vessel failure (TVF) at 12 months for comparison of DAPT duration. The results indicated that the six-month DAPT strategy was non-inferior to the standard care. Additionally, although there was a numerical increase in TIMI major and minor bleeding in the 12-month group, this difference was not statistically significant (HR 0.40; 95% CI: 0.13–1.27; p = 0.12) [
63].
The PRODIGY (PROlonging Dual antIplatelet treatment after Grading stent-induced intimal hYperplasia study) trial was a 4:2 randomized open-label clinical trial that evaluated the efficacy and the safety of prolonged DAPT with clopidogrel as P2Y12 inhibitor, randomly allocating patients (predominantly presenting with ACS) to treatment with four coronary stents (BMS, paclitaxel-eluting stent, E-ZES, everolimus-eluting stent) and two DAPT duration strategies (6 vs 24 months’ DAPT). The study showed no differences in the primary efficacy endpoint of death, MI, and stroke between 6 and 24 months DAPT, and, as expected, among the patients receiving 24-months DAPT, there was a risk of type 2, 3 or bleeding events two-folds greater than the group receiving 6-months DAPT (HR 2.17, 95% CI 1.44-3.22; p=0.00018) [
64]. Results remained largely consistent in multiple subgroups [
65,
66,
67].
The REDUCE trial, randomized 1,496 ACS patients treated with COMBO stent to 3 or 12 months of DAPT. The composite primary study endpoint of all-cause mortality, MI, ST, stroke, target vessel revascularization and bleeding at 12 months was similar in the two groups, reaching prespecified non-inferiority (8.2% vs 8.4%, pnon-inferiority<0.001). However, numerically higher rates of mortality and ST in the three-month DAPT group were observed [
68]. The non-inferiority of 3 vs 12 months DAPT was confirmed in several high-risk subgroups [
69,
70,
71].
3.4. Individualization Of DAPT Duration Based on Ischemic And Bleeding Risk
The optimal DAPT strategy, that maximize the efficacy and the safety of the treatment, balancing ischemic and bleeding risk, should be individual and selected based on patient’s and procedural characteristics (
Figure 3) [
72,
73,
74].
The clinical presentation (ACS vs CCS) at the time of PCI is an important feature that influences the patient’s mortality risk (ranging between 0.36% in CCS and 4.78% in high-risk STEMI patients), and the risk of recurrent ischemic events [
75,
76]. Clinical presentation in the setting of an all-comer PCI population is also a treatment modifier of DAPT duration after coronary stenting. Costa et al. conducted an analysis of the PRODIGY (Prolonging DualAntiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study) trial, a study designed to compare 6- or 24-month DAPT regimens in patients treated with PCI and receiving a balanced mixture of stents with varying anti-intimal hyperplasia potency and belonging to both first and second generation DES. It showed the lack of ischaemic benefit in favour of a 24-month course of DAPT, in both CCS and ACS patients. Both in CCS and ACS patients the rate of bleeding was higher in the 24-month DAPT arm, with a greater magnitude in patients presenting with CCS. In terms of NACE rates, after excluding BARC 2 bleeding, appeared a numerical increase of NACE in CCS patients only, with interaction testing providing consistent borderline results in the 24-months DAPT arm. So, this analysis suggested that clinical presentation is a treatment modifier with respect to the value of prolonged vs. shortened DAPT duration [
67].
In the DAPT trial, a randomized double-blind, placebo-controlled trial comparing 30 versus 12 months of dual antiplatelet therapy after coronary stenting, 30-month DAPT compared with 12-month treatment significantly reduced definite or probable ST both in patients with MI (0.5 vs 1.9%; p= 0.001) and without MI (0.4 vs 1.1%; p= 0.001) (Pint = 0.69). Yet, the reduction of MACCE from longer DAPT was greater for patients with MI (3.9 vs 6.8%; p \ 0.001) than patients without MI (4.4 vs 5.3%; p = 0.08) at the time of presentation, with a positive interaction testing (Pint = 0.03). Of 11,648 randomized patients (9961 treated with drug-eluting, 1687 with bare metal stents), 3,576 (30.7%) presented with MI. Importantly, longer DAPT was associated with a significant increase in all- cause death among patients presenting without MI (2.1 vs 1.5%; p = 0.04) [
57].
The ischemic risk after PCI is also associated to several anatomical or procedural characteristic. This is why they have been consistently considered important elements to be taken into account for decisions around DAPT duration [
77,
78]. The complexity of a PCI can be quantified using previously validated and guideline-endorsed criteria: PCI with ≥3 stents implanted and 3 ≥ lesions and/or coronary vessels treated; and/or bifurcation with 2 stents implanted, total stent length >60 mm, and/or treatment of a chronic total occlusion (CTO). In these patients, long-term DAPT (≥12 month) compared with a short period of DAPT (three or six months), significantly reduced the risk of cardiac ischemic events [
79].
Even the localization of the coronary artery stenosis should be considered a treatment modifier for DAPT duration, as suggested by Costa et al. in a retrospective analysis of the PRODIGY trial. In patients with a lumen stenosis of at least 30% on angiography, appraised by visual estimation, of the Left main or the proximal LAD twenty-four DAPT regimen, compared to six-month DAPT significantly reduced the rate of definite, probable, or possible ST. A consistent trend towards interaction between CAD location and DAPT duration was also noted for the composite of CV death and MI. The 24-month DAPT regimen remained associated with possible benefits in patients with LM/pLAD lumen narrowing irrespective of whether a stent was or was not implanted in these segments or whether patients presented with acute coronary syndrome [
80].
In a patient-level meta-analysis from six RCTs (N = 9577) investigating DAPT durations (12 vs 6 months) after coronary stenting, 17.5% of patients had at least one of the characteristics of complex PCI (three-vessel PCI, and/or an implantation of three or more coronary stents, and/or three or more coronary lesions, and/or bifurcation stenting, i.e., bifurcation technique using stents in both the main and the side branch, and/or a final total stent length 60 mm, and/or treatment of a CTO). In this group, long DAPT compared with short DAPT reduced the adjusted MACCE rate (unadjusted event rates: 4.0 vs 6.0%; adjusted HR 0.56, 95% CI 0.35–0.89), whereas no benefit for a longer treatment was observed in the non-complex PCI group (2.5 vs 2.6%; adjusted HR 1.01; 95% CI 0.75–1.35) (Pint = 0.01). The magnitude of benefit in favor of long DAPT was directly and positively related to the number of complex PCI factors [
81].
Concomitant high bleeding risk can mitigate the benefit from a longer DAPT regimen in patients undergoing a complex PCI. In an analysis that included 14,963 patients from 8 randomized trials, long-term DAPT in non-HBR patients reduced the ischemic events in both complex and noncomplex PCI, but not among HBR (PRECISE-DAPT > 25) patients, regardless of complex PCI features [
82].
3.5. Optimal DAPT Duration in HBR Patients
The optimal duration of DAPT in high bleeding risk patients (HBR) has been recently explored. DAPT leads to a significant increase of the rate of major bleeding, associated with greater risks of adverse cardiac outcomes. Major bleeding is associated with an immediate and sustained increased risk of mortality, similar or greater than recurrent MI, easily offsetting the benefit of its ischemic protection. Roughly one out of three patients undergoing PCI is at HBR (i.e., patients with older age, low hemoglobin level, thrombocytopenia, renal insufficiency, cancer, a prior stroke, and a bleeding history) [
25]. HBR features are also associated with an increased ischemic risk. These patients are considered to be at double-sided risk: high risk for bleeding, and high risk for recurrent ischemic or thrombotic events, that’s why weighing in ischemic and bleeding risk to decide the optimal DAPT strategy is a challenge for the clinician [
83].
The current guidelines endorse the use of a standardized tool, the predicting bleeding complications in patients undergoing stent implantation and subsequent DAPT therapy (PRECISE-DAPT) score for bleeding risk stratification [
84]. The PRECISE-DAPT score was developed to predict the bleeding risk in patients undergoing PCI and, therefore, a DAPT regimen. This score is based on five features clinical and laboratoristic features: age, white blood cell count, hemoglobin level, creatinine clearance, and history of spontaneous bleeding. Patients with a score of ≥25 are at a high risk of bleeding, indicating that the DAPT duration should be shorter (3 to 6 months) than that in patients with a score of < 25. To derive and validate the score, Costa et al., pooled 14 963 patients treated with DAPT after coronary stenting from eight multicentre randomized clinical trials. Using Cox proportional hazards regression, predictors of TIMI major or minor bleeding were identified, and based on them, a numerical score was developed. A derivation cohort of patients was used to assess the predictive performance of the score and it was validated in validation cohorts of patients from the PLATO trial (n=8595) and BernPCI registry (n=6172). In patients identified at high risk (score ≥25), a longer DAPT duration significantly increased bleeding, but not in those with lower risk profiles [
85]. Multiple external validations of this prediction tool have been presented largely confirming the score discriminative ability [
86,
87].
A simplified version of the score, the 4-item PRECISE-DAPT, lacking white blood cells count, has been studied to know if it has potential to guide DAPT. In an analysis carried out in a pooled dataset of 5 randomized studies and including more than 10,000 patients, it showed that it may be useful to support clinical decision-making for DAPT duration [
88].
The Academic Research Consortium for High Bleeding Risk (ARC-HBR), a collaboration of leading research organizations, regulatory authorities, and physician-scientists from the United States, Asia, and Europe focused on PCI–related bleeding, elaborated a standardized definition of HBR patients, based on review of the available evidence. Twenty clinical criteria were identified as major or minor by the consensus. Patients are considered to be at HBR if at least 1 major or 2 minor criteria are met. The coexistence of numerous numbers of risk factors is associated with a linear increase in risk of BARC 3 to 5 bleeding. Multiple external validations of this classification have been recently published [
89].
The optimal DAPT duration for limiting bleeding risk while not reducing ischemic protection, was investigated in the MASTER DAPT trial. MASTER-DAPT was the first randomized trial to demonstrate that among HBR patients undergoing coronary stenting with a bioresorbable polymer-based sirolimus-eluting stent, abbreviating DAPT to 1 month was non-inferior to a standard DAPT for 6 months or more in terms of NACE, or major adverse cardiac or cerebral events, and superior in terms of major or clinically relevant non-major bleeding (MCRB). The trial enrolled patients, regardless their clinical presentation, that had undergone successful PCI with implantation of a biodegradable-polymer sirolimus-eluting stent (Ultimaster, Terumo), at HBR. Patients had to be free from ischemic and active bleeding events at the moment of the randomization. They were randomly assigned to an abbreviated DAPT regimen (i.e., stopped DAPT after 30 days and continued SAPT; abbreviated-therapy group) or to standard DAPT regimen (i.e., 6 months after the index procedure; standard-therapy group). The aim of the trial was to test whether the abbreviated dual antiplatelet therapy, was noninferior in terms of net adverse clinical events (NACE), major adverse cardiac or cerebral events (MACCE), and superior with regard to major or clinically relevant bleeding, compared to standard regimen. The trial showed that in patients at high risk for bleeding, the discontinuation of DAPT at a median of 34 days after PCI led to a reduction of the incidence of major or clinically relevant non-major bleeding (6.5% in the abbreviated-therapy group and 9.4% in the standard-therapy group) and was noninferior with regard to NACE and MACCE compared to standard treatment [
90].
The XIENCE 28 and XIENCE 90 studies, were two prospective, single-arm studies, that compared 1 month DAPT regimen (XIENCE 28) and 3 months DAPT regimen (XIENCE 90), in patients HBR undergone successful PCI with a Xience stent implanted, a durable polymer everolimus-eluting stent, with 12-months DAPT, testing the hypothesis that would be non-inferior in terms of ischemic events and superior with respect to bleeding events. A total of 3652 patients, free from MI, repeat coronary revascularization, stroke, or ST, were randomized to 1 month (1605) or 3 months (2047) DAPT. Patients that presented with STEMI, or with a left ventricular ejection fraction < 30% were excluded. Most of the patients continued with ASA after DAPT discontinuation. The primary study endpoint was all-cause death or all MI, the secondary endpoints were BARC 2-5 bleeding and definite/probable ST. The studies present limitations inherent to the non-randomized design. A short DAPT regimen of 1 or 3 months resulted non-inferior with respect to ischemic outcomes, had similar rates of clinically relevant (BARC 2-5) bleeding, with a significant reduction in major (BARC 3-5) bleeding and a very low incidence of stent thrombosis [
91,
92].
A recent metanalysis of RCTs, searched studies comparing abbreviated (1 month) or short (3 months) with standard (≥6 months) DAPT in HBR patients (PRECISE-DAPT > 25) without indication for oral anticoagulation, to estimate the impact of this abbreviated DAPT regimens in this setting of patients. Articles were initially screened by title and abstract content. A total of 11 RCTs, including 9006 patients treated with PCI who were randomized to abbreviated (≤3 months) or standard (≥6 months) DAPT durations, and reporting outcome data for bleeding and ischemic endpoints at a minimum follow-up of 12 months after enrollment were included. A lower rate of major or clinically relevant non-major bleeding, major bleeding and CV mortality was registered with the abbreviated DAPT regimens, with no significant differences in terms of prevention of MACE, ST, and other ischemic events, irrespective of clinical presentation and P2Y12i used (
Figure 4) [
93].
The risk factors for both bleeding and ischemic events can intersect, leading to an ongoing debate regarding the most effective approach to reduce both types of events in this particular patient population. The OPT-BIRISK trial is a multicentre, double-blind, placebo-controlled superiority trial comparing clopidogrel monotherapy with DAPT, aspirin and clopidogrel, in patients with both high bleeding and ischaemic risk who have completed 9-12 months of DAPT post PCI for ACS. The primary endpoint of BARC 2, 3 or 5 bleeding and the key secondary endpoint of MACCE (a composite of all-cause mortality, MI, stroke or clinically driven revascularisation) were lower in the clopidogrel monotherapy arm, 2.5% vs. 3.3%, (HR 0.75, 95%CI 0.57-0.97, p=0.03) and 2.6%. vs 3.5%, (HR 0.74, 95%CI 0.57-0.96, p=0.02). The majority of patients enrolled in the study presented with unstable angina, which could potentially influence the observed outcomes. However, it’s important to consider that patients were not randomized into treatment groups until 9-12 months after undergoing PCI. This timing suggests that the patient population was transitioning toward the chronic phase within the spectrum of ACS/CCS [
94].
3.6. Patients Treated on Long-Term OAC
The need for the association of antiplatelet and anticoagulant therapies is frequent, mostly in patients affected by atrial fibrillation that need thromboembolic prevention (AF) undergoing PCI or with concomitant ACS (condition that occurs in about 10% of cases of hospital admission for ACS) [
95]. Anticoagulant therapy is inferior to antiplatelet therapy after stent implantation to prevent recurrent ischemic events and ST, on the other hand, antiplatelet therapy is inferior to anticoagulant therapy to prevent stroke and systemic embolism in patients with AF [
96]. However, the combination of antithrombotic agents, triple therapy with oral anticoagulation and dual antiplatelet therapy (TAT), exposes the patient to an excessive bleeding hazard (3-4 times higher than the two treatments considered alone) [
97]. Hence the patient needing long-term oral anticoagulation is considered HBR per se.
Considering that long term OAC therapy is mandatory in this setting, reducing DAPT duration has been widely explored in multiple clinical trials, testing the hypothesis of removing one antiplatelet agent early after stenting, downgrading TAT to a dual antithrombotic therapy (DAT) [
98].
Several studies focused the attention on this clinical setting, studying the duration and the intensity of the antithrombotic treatment. Multiple trials evaluated, in patients with AF undergoing PCI, safety and efficacy of a DAT therapy approach with a NOAC compared with a triple antithrombotic therapy with a vitamin K antagonist [
99,
100].
The PIONEER AF-PCI trial, randomized 2124 patients affected by non-valvular AF treated with PCI, to receive DAT consisting of low-dose rivaroxaban (15 mg die) plus a P2Y12 inhibitor; very low-dose rivaroxaban (2.5 mg die) plus DAPT, or VKA plus DAPT. At 12 months, the study showed a lower rate of relevant bleeding in the groups not receiving a VKA, with the lowest rate in the low-dose rivaroxaban group (6.8% for rivaroxaban 15 mg + P2Y12i, 18.0% for rivaroxaban 2.5 mg + 26.7% for VKA + DAPT). Rates of ischemic events did not significantly differ in the three groups [
99].
The AUGUSTUS trial, a randomized trial with 2:2 factorial design, enrolled 4614 patients with AF who had an ACS or had undergone PCI and were planning to take a P2Y12 inhibitor and randomized them to receive apixaban or a vitamin K antagonist and to receive aspirin or placebo for 6 months. AUGUSTUS is the first trial to test both the concept of OAC type and dual vs. triple therapy separately. At six-month follow-up, the primary endpoint, the rate of MCRB, was 10.5% of the patients receiving apixaban, as compared with 14.7% of those receiving a VKA. With respect to the second randomization, the primary endpoint occurred in 16.1% in the aspirin group, as compared to 9.0% in the placebo group (HR, 1.89; 95% CI, 1.59–2.24; p < 0.001). With respect to ischemic events, the rate was similar among patients treated with apixaban or VKA and also for patients randomized to aspirin or placebo. Ischemic stroke was significantly reduced by 50% among patients in the apixaban arm. In conclusion, in patients with AF and a recent ACS or PCI both dual therapy and apixaban were associated to a reduction of bleeding without an increase in ischemic events [
101].
The impact of dual or triple therapy in HBR patients undergoing PCI has been evaluated in a subgroup analysis of the REDUAL PCI trial. In this study, DAT with dabigatran 110mg bid reduced bleeding risk in both patients at HBR and non-HBR. In turn, DAT with dabigatran 150mg compared to warfarin based TAT, reduced bleeding in non-HBR patients but not in HBR patients, with a trend towards less benefit in HBR patients [
102].
Importantly, while most of the trials tested a DAT approach linked to NOAC and a TAT linked to VKA [
103,
104], it is important to unravel the true benefit associated to dual therapy beyond those given by a treatment with NOAC, which per se is associated to less bleeding compared to VKA. On this matter, Montalto et al. performed a systematic review evaluating randomized controlled trials comparing an abbreviated (4-6 weeks) or prolonged (>= 3 months) DAPT regimen in patients with OAC. Co-primary endpoints were MCRB and major bleeding, while the rate of MACE was endpoint for safety. Five studies were included, for a total of 7665 patients, 3843 treated with abbreviated DAPT and 3822 with prolonged DAPT. MCRB and major bleeding were lower with abbreviated DAPT [risk ratio (RR) 0.69 (0.52-0.91); P = 0.01 and 0.70 (0.52-0.95); P = 0.01, respectively] while the rate of MACE and other ischemic events (CV death, ST, MI) did not differ. Network meta-analysis showed that peri-procedural DAPT had the highest probability to be the best treatment in preventing MCRB and major bleeding when compared with both short and longer DAPT strategies [
105].